FDA grants RMAT status for BlueRock’s Parkinson’s therapy

[Baron1]

Good Morning or Evening All,

Is this another "Teaser"or could this be ready and available for patients in the near future ?

Food and Drug Administration (FDA) has granted a regenerative medicine advanced therapy (RMAT) designation for BlueRock Therapeutics’ investigational cell therapy Bemdaneprocel (BRT-DA01) for Parkinson’s disease.

Bemdaneprocel is claimed to be the most clinically advanced cell therapy for Parkinson’s disease treatment in the US.The therapy is created to replace the dopamine-producing neurons lost in the course of the disease.

Data from the trial, announced in March 2024, indicated that Bemdaneprocel was well tolerated and did not present major safety issues up to 18 months post-treatment.

Furthermore, an increase in the F-DOPA PET imaging signal was observed after the cessation of immune suppression therapy at 12 months, suggesting that the transplanted cells survive and en-graft in the brain.

Best Wishes to All.

[Boscoejean]

so does this mean more research or providing this to someone who can afford it?

[jeffreyn]

See also this recent post:

healthunlocked.com/cure-par...